---
title: 'Regulatory Daily Summary: What Happened on November 15, 2026'
headline: FDA rejects Summit and Akeso’s ivonescimab for lung cancer
description: The agency said the drug did not extend patients’ lives, despite slowing
  disease progression.
url: https://thebench.bio/news/regulatory/2026-11-15
topic: regulatory
date: '2026-11-15'
covers:
- '2026-11-15'
date_published: '2026-11-16T00:00:40Z'
date_modified: '2026-11-16T00:00:40Z'
tags:
- Regulatory
sources: 1
publisher: TheBench.Bio
---

# Regulatory Daily Summary: What Happened on November 15, 2026

**FDA rejects Summit and Akeso’s ivonescimab for lung cancer**

The agency said the drug did not extend patients’ lives, despite slowing disease progression.

## Today in brief

The FDA turned down ivonescimab, developed by Summit Therapeutics and Akeso for a type of lung cancer, because it had not extended patients’ lives. [1] Although the drug slowed cancer progression, FDA reviewers said the result did not support a favorable benefit-risk profile for approval. [1]

## FDA says ivonescimab did not show a survival benefit

Summit said the FDA rejected ivonescimab, which Summit and Akeso developed for a type of lung cancer. [1] The agency said in its letter to the companies that the treatment could not be approved because it had not extended patients’ lives. [1]

Ivonescimab slowed the worsening of patients’ cancer, but FDA reviewers concluded that the result did not establish a favorable balance of benefits and risks for approval. [1]

## Also published

- [FDA won't approve Summit, Akeso's ivonescimab](<https://pharmaphorum.com/news/fda-wont-approve-summit-akesos-ivonescimab>), pharmaphorum

## Sources

1. [STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics](<https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/?utm_campaign=rss>), STAT Biotech, 2026-11-15

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/?utm_campaign=rss>
